RA Capital Nexus Fund III, L.P. Sells Common Stock of Sionna Therapeutics, Inc.

RA Capital Nexus Fund III, L.P., a 10% stockholder and director of Sionna Therapeutics, Inc., has filed a Form 144 notice indicating its intent to sell 66,672 shares of common stock. The shares were acquired during the company's IPO on February 7, 2025. The sale is expected to take place on or around October 24, 2025, with an aggregate market value of approximately $2,614,209.12. The transaction will be executed through BTIG, LLC. The filing also confirms that there have been no other sales of securities by RA Capital Nexus Fund III, L.P. in the past three months.